Docetaxel/ TS-1 with radiation for unresectable squamous cell carcinoma of the esophagus - A phase II trial

Medicine and Dentistry

• Phase II Trials 100%
• Esophagus 66%
• Patient 50%
• Docetaxel 50%
• Neoplasm 33%
• Adverse Event 33%
• Organ 33%
• Combination Therapy 16%
• Therapeutic Procedure 16%
• Metastatic Carcinoma 16%
• Surgery 16%
• Survival Rate 16%
• Chemoradiotherapy 16%
• Median Survival Time 16%
• Rest 16%
• Potassium 16%
• Tegafur 16%
• Gimeracil 16%
• Thoracic Wall 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Radiation 100%
• Docetaxel 50%
• Adverse Event 33%
• Neoplasm 33%
• Squamous Cell Carcinoma 33%
• Combination Therapy 16%
• Metastasis 16%
• Survival Rate 16%
• Median Survival Time 16%
• Potassium 16%
• Tegafur 16%
• Gimeracil 16%

Biochemistry, Genetics and Molecular Biology

• Radiation 50%
• Survival Rate 16%
• Rest 16%
• Median Survival Time 16%
• Tegafur 16%